Contribute Try STAT+ Today

Among scientists around the world, Eli Broad’s name will forever be tied to the role the institute he founded played in helping the Boston and Cambridge area emerge from the global pandemic, and the foundation it provided for researchers who are seeking to identify and contain variants of the Covid-19 virus.

But Broad, who died April 30, also will be remembered by families, such as the Chakrabartis in Cambridge, for what the Broad Institute of MIT and Harvard has done on an individual level, bringing the intellectual clout of a major research institute to bear on a rare illness.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.